



Article

HPLC/ESI-MS and NMR Analysis of Chemical Constituents in Bioactive Extract from the Root Nodule of *Vaccinium emarginatum*

Hsiang-Ming Huang^{1,†}, Chien-Yi Ho^{2,3,†}, Geng-Ruei Chang⁴ , Wei-Yau Shia⁵, Cheng-Hung Lai⁵, Chih-Hao Chao^{6,*} and Chao-Min Wang^{4,*}

¹ Neurosurgery Department, China Medical University Hsinchu Hospital, Hsinchu 302, Taiwan; d10190168@gmail.com

² Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 404, Taiwan; samsam172@yahoo.com.tw

³ Division of Family Medicine, Physical Examination Center, and Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu 302, Taiwan

⁴ Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 600, Taiwan; grchang@mail.ncyu.edu.tw

⁵ Department of Veterinary Medicine, National Chung-Hsing University, 145 XingDa Road, Taichung 402, Taiwan; vmwyshia@nchu.edu.tw (W.-Y.S.); chlai@dragon.nchu.edu.tw (C.-H.L.)

⁶ Division of Chest Medicine, Attending Physician of Chang Bing Show Chwan Memorial Hospital, 6 Lugong Road, Lukang Township, Changhua 505, Taiwan

* Correspondence: drchao028@gmail.com (C.-H.C.); leowang@mail.ncyu.edu.tw (C.-M.W.); Tel.: +886-975-617918 (C.-H.C.); +886-5-2732970 (C.-M.W.)

† These authors contributed equally to this work.



Citation: Huang, H.-M.; Ho, C.-Y.; Chang, G.-R.; Shia, W.-Y.; Lai, C.-H.; Chao, C.-H.; Wang, C.-M. HPLC/ESI-MS and NMR Analysis of Chemical Constituents in Bioactive Extract from the Root Nodule of *Vaccinium emarginatum*. *Pharmaceuticals* **2021**, *14*, 1098. <https://doi.org/10.3390/ph14111098>

Academic Editor: Sabesan Yoganathan

Received: 24 September 2021
Accepted: 27 October 2021
Published: 28 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: *Vaccinium emarginatum* Hayata is a medicinal plant that has been historically used in ethnopharmacy to treat diseases in Taiwan. The objective of this study is to evaluate the anti-cancer and anti-bacterial constituents from the root nodule extract of *V. emarginatum*. The chemical composition of *V. emarginatum* fractions was analyzed by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) and the chemical constituents were isolated and structurally identified by nuclear magnetic resonance (NMR) spectroscopy. Bioassay-guided chromatography showed that the ethyl acetate (EA) fraction was bioactive on the hepatocellular carcinoma (HepG2). By LC-ESI-MS/MS analysis, twenty peaks of EA fraction were partially identified and the phytochemical investigation of the fractions led to the isolation and identification of protocatechuic acid (1), epicatechin (2), catechin (3), procyanidin B3 (4), procyanidin A1 (5), hyperin (6), isoquercetin (7), quercetin (8), lupeol (9), beta-amyrin (10), and alpha-amyrin (11). Both procyanidin B3 and A1 exhibited anti-proliferative activity against HepG2 and gastric adenocarcinoma (AGS) cells at IC₅₀ values between 38.4 and 41.1 μM and 79.4 and 83.8 μM, respectively. In addition, isoquercetin displayed the strongest anti-proliferative activity against the HepG2, lung carcinoma (A549), and AGS cell at 18.7, 24.6 and 68.5 μM, respectively. Among the triterpenoids, only lupeol showed the inhibitory activity against all tested tumor cell lines at IC₅₀ values between 72.9 and 146.8 μM. Furthermore, procyanidins B3, A1 and isoquercetin displayed moderate anti-bacterial activity against *Staphylococcus aureus*. In conclusion, this study provides background information on the exploitation of *V. emarginatum* as a potential natural anti-cancer and anti-bacterial agent in pharmaceutical research.

Keywords: *Vaccinium emarginatum*; anti-cancer; anti-bacterial; procyanidins

1. Introduction

The genus *Vaccinium* comprising approximately 450 species in the family *Ericaceae*, is a common and widespread genus of morphologically diverse terrestrial shrubs. *Vac-*

cinium is a class of berry fruits including blueberries (*V. corymbosum*), bilberries (*V. myrtillus*), lingonberries (*V. vitis-idaea*), and cranberries (*V. macrocarpon*), which are consumed by humans [1]. It has been reported as one of the rich sources of naturally occurring bioactive phytochemicals, including phenolic acids, flavonoids, anthocyanins, proanthocyanidins and tannins [2–5]. *Vaccinium* berries are well-known for their high antioxidant metabolite contents, which have high potential in anti-oxidant [6,7], anti-bacterial [7], anti-inflammatory [8,9], anti-diabetic [10,11], and anti-proliferative activities [12,13]. According to their broad-spectrum activities, various *Vaccinium* leaf and berry extracts have been developed as commercial products for dietary supplements [14,15].

Vaccinium emarginatum Hayata (*Ericaceae*) is an endemic species distributed across central mountain regions in Taiwan at an elevation of 1500–3000 m [16]. Unlike other *Vaccinium* species, it is an epiphytic shrub growing on the branches of trees in the broad-leaved forests with enlarged root nodules storing the water and nutrients (Figure 1). In Taiwan, the root nodules are used in traditional medicine, which is supposed to be as effective as Lu Rong (the developing antlers of deer; velvet antler). Its leaves are used to treat urinary tract infections and rheumatic pain, while the fruits are used to treat dysentery and enteritis, respectively [9].



Figure 1. *V. emarginatum* Hayata is an epiphytic shrub grow on the branch of the tree (A) in the broad-leaved forests (C) with enlarged root nodules (B) storing the water and nutrients.

To date, few phytochemical studies were reported for *V. emarginatum* [5,9]. Previously, one epicatechin derivative and three new flavonoids, emarginin A, B, and C, were isolated from the methanolic extract of the whole plants of *V. emarginatum*. Emarginin C exhibited moderate anti-inflammatory activity [5]. Recently, the cytotoxic and anti-inflammatory activity of terpenoids from the whole plant of *V. emarginatum* was also investigated [9]. Although those studies indicated the high potential of *V. emarginatum* in anti-inflammatory and cytotoxicity against prostate cancer cells, the anti-infective activity on human pathogens and anti-proliferative effect on tumor cells are still unknown. The object of this study is to evaluate the anti-proliferative and anti-bacterial activities of different chemical fractions from *V. emarginatum* methanol extracts and to characterize its phytochemical profile. The chemical composition of bioactive fraction was further analyzed by LC-ESI-MS/MS, and the chemical constituents were isolated and structurally identified by NMR. Finally, the anti-proliferative activities of isolated compounds were determined by measuring the IC_{50} of hepatocellular carcinoma (HepG2), lung carcinoma (A549) and gastric adenocarcinoma (AGS). The anti-bacterial activities of isolated compounds were also tested against seven bacterial pathogens by minimum inhibitory concentration (MIC)

methods. It is suggested that all of these isolated compounds may have the potential in clinical treatment as therapeutic agents in the future.

2. Results

2.1. Biological Activity of *V. emarginatum* Extract

2.1.1. Anti-Proliferation Activity of the *V. emarginatum* Extract on HepG2 Cell Line

The cytotoxic effect of different fractions of *V. emarginatum* extract was examined on the HepG2 cell line over 72 h. Aliquots of DCM (dichloromethane), EA (ethyl acetate), BuOH (n-butanol), and water fractions (for a concentration range from 2.5 to 40 µg/mL) were evaluated for the anti-proliferative activity. The DCM and BuOH fractions displayed moderate cytotoxicity, with a relative cell viability of 91.6% to 93.9%, and 86.3% to 96.9% on HepG2 cells, respectively, in comparison with the control (Figure 2). It was revealed that the EA fractions exhibited dose-dependent inhibitory activities on the HepG2 cell, with a relative cell viability of 65.9% to 85.6%. The results show that the HepG2 cell was potentially inhibited by the EA fraction of *V. emarginatum* extract.




Figure 2. The anti-proliferative activity of different fractions from *V. emarginatum* on human hepatocellular carcinoma cells (HepG2 cell line). The HepG2 cells were treated with a different concentration from 0 to 40 µg/mL of DCM (dichloromethane), EA (ethyl acetate), BuOH (n-butanol), and water fractions of *V. emarginatum*. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

2.1.2. Anti-Bacterial Activity of the *V. emarginatum* Extract by the Disc Diffusion Method

Seven strains of pathogens, including *Staphylococcus aureus* (ATCC 43300), *Enterococcus faecalis* (ATCC 29212), *Listeria monocytogenes* (ATCC 7644), *Bacillus cereus* (ATCC 9139), *Escherichia coli* (ATCC 35150), *Salmonella enterica* (ATCC 13311), and *Pseudomonas aeruginosa* (ATCC 27853), were selected to evaluate the anti-bacterial activity. Among all of the partitioned fractions, ethyl acetate (EA) fractions and the butanol (BuOH) displayed higher anti-bacterial activity against all tested pathogens. The BuOH fraction presented a slightly lower anti-bacterial activity than the EA fraction. As shown in Table 1, the EA fraction of *V. emarginatum* extract showed anti-bacterial activity against the test strains of *S. aureus*, *E. faecalis*, *L. monocytogenes* and *B. cereus* with average inhibition zones of 14, 7, 9 and 10 mm by using the disc diffusion assay. The EA-15 fraction revealed the most significant and broad anti-bacterial spectrum against the strains of *S. aureus*, *E. faecalis*, *L. monocytogenes* and *B. cereus*, with average inhibition zones of 18, 9, 12 and 14 mm, respectively.

Table 1. The anti-bacterial activity of different fractions from *V. emarginatum* against human pathogens by the disc diffusion method.

Pathogens	Disc Inhibition Zone (mm)				
	DCM *	EA	BuOH	H ₂ O	EA-15
<i>Staphylococcus aureus</i>	0	14.3 ± 0.6	12.3 ± 0.6	0	18.3 ± 0.6
<i>Enterococcus faecalis</i>	0	7.0 ± 0.0	0	0	9.0 ± 0.0
<i>Listeria monocytogens</i>	0	9.0 ± 0.0	7.0 ± 0.0	0	12.3 ± 0.6
<i>Bacillus cereus</i>	0	10.3 ± 0.6	9 ± 0	0	14.3 ± 0.6
<i>Escherichia coli</i>	0	0	0	0	0
<i>Salmonella enterica</i>	0	0	0	0	0
<i>Pseudomonas aeruginosa</i>	0	0	0	0	0

* DCM: dichloromethane; EA: ethyl acetate; BuOH: n-butanol.

2.2. LC-ESI-MS/MS Analysis of EA Fraction of *V. emarginatum* Extract

The chromatographic profile EA fraction of *V. emarginatum* extract was determined through LC-ESI-MS/MS analysis (Figure 3). The data of both positive and negative MS and MS² spectra were obtained and the component of the EA fraction was identified partially according to the literature.

As shown in Table 2, twenty-two peaks can be characterized and twenty peaks can be identified by comparing the spectrum data to references reported previously. For example, loss of CO₂ was observed for dihydroxyisophthalic acid and protocatechuic acids, giving the [M–H–44][–] as a characteristic ion [17]. As described by Sanchez-Rabaneda F. et al., catechin and epicatechin generated a loss of a –CH₂CHOH– group (*m/z* 245) [17]. Peak 11 showed free (epi)catechin ions at *m/z* 289, indicating condensed tannin dimers consisting of (Epi)afzelechin-(Epi)catechin at *m/z* 561 [18].

For Peaks 2, 4 and 10, the [M–H][–] ion at *m/z* 577 suggested the procyanidin dimer with a B-type linkage. Elimination of a phloroglucinol molecular from the B-type dimer resulted from the ion products of MS² at *m/z* 451 [M–H–126][–]. Ions at *m/z* 407 [M–H–170][–] and *m/z* 289 [M–H–288][–] were all suggested by the B-type procyanidin dimer (Table 2) [19]. Those peaks were identified as procyanidin B1, B2 and B3 according to the literature and isolated chemicals [19]. For Peak 6 and 13 in Figure 3, the [M–H][–] ion at *m/z* 863 (M.W. 864) suggested an A-type procyanidin trimer with an interflavanoid linkage (Table 2). According to the ion products of the MS² of Peak 6, ions at the *m/z* 711 [M–H–152][–], *m/z* 693 [M–H–152 – 18][–] compound in Peak 6 were identified as A-type procyanidin trimer [19]. Furthermore, Peak 13 was identified as procyanidin A1 according to the literature and isolated chemicals.

Fragmentation pattern of Peaks 9, 11, 15 and 16 displayed the diagnostic ions at *m/z* 301, suggesting that these compounds were quercetin and quercetin derivatives [20]. For the hyperin and isoquercetin, the spectra showed the ion related to the deprotonated aglycone [A – H][–], which is formed by loss of the galactose or glucose moiety from the flavonol glycosides [17]. The fragmentation pattern of Peaks 17, 18, 19 and 20 contained a negative ion at *m/z* 425 [M–H][–] and a positive ion at 427 *m/z* 427 [M + H]⁺, suggesting the structure of C₃₀H₅₀O. Observed ions' *m/z* corresponds to [M–H–H₂O][–], [M–H–2H₂O][–], and [M–H–H₂O – CH₂CHOH][–] at 407, 389 and 363, indicating the structure of triterpenoid. In addition, the peaks were identified as lupeol, β-amyrin, α-amyrin and friedelin according to the retention time, the literature and the isolated chemicals in this study [21–23].




Figure 3. (A). LS-ESI-MS chromatograms of EA fraction of *V. emarginatum* extract in positive (+) and negative (−) ionization modes. (B). Extraction Ion Chromatograms of Isolated Compounds (1–11) in negative (−) ionization modes.

Table 2. Characterization of compounds in EA fraction of *V. emarginatum* using LCESI-MS/MS in negative ion mode.

No.	R.T. (min)	Assigned Identity	Mass	M.W.	Negative ESI-MS ⁿ <i>m/z</i> (% Base Peak)	Reference
1	7.2	Protocatechuic acid	[M−H] [−] : 152.8 [M+H] ⁺ : 154.9	154	108.9(100)	[17]
2	8.3	Procyanidin B1	[M−H] [−] : 577.1 [M+H] ⁺ : 579.2	578	407.0(100), 425.0(63), 288.9(26.5), 451(17.9), 559.1(9.1)	[24]
3	9.5	Catechin	[M−H] [−] : 289 [M+H] ⁺ : 291	290	270.8(6.3), 244.8(100), 230.7(8.2), 204.7(38.8), 202.7(22.0), 178.8(10.8), 160.7(8.4)	[17,24]

Table 2. Cont.

No.	R.T. (min)	Assigned Identity	Mass	M.W.	Negative ESI-MS ⁿ <i>m/z</i> (% Base Peak)	Reference
4	10.8	Procyanidin B2	[M–H] [−] : 577.1 [M+H] ⁺ : 579.2	578	559.1(8.2), 450.9(15.7), 424.9(74.8), 407.0 (100), 288.9(24.3)	[24]
5	12.4	Epicatechin	[M–H] [−] : 288.8 [M+H] ⁺ : 290.9	290	270.7(5.3), 244.7 (100), 230.7(11.3), 204.7(47.8), 202.8(31.6), 178.7(13.6), 160.7(7.5)	[17,24]
6	14.7	A-type Procyanidin trimer	[M–H] [−] : 863.1 [M+H] ⁺ : 865.2	864	711.1 (100), 411(61.8), 559.1(50.8), 693.1(43.3), 712(23.1), 451(22.9), 694.1(20.9)	[19]
7	17.8	Emarginin B	[M–H] [−] : 358.9 [M+Na] ⁺ : 383.0	360	196.7 (100), 152.8(34.3), 134.8(20.3), 108.9(7.8)	[5]
8	18.6	Dihydroxyisophthalic acid	[M–H] [−] : 196.7 [M+H] ⁺ : 198.9	198	152.8 (100), 134.8(3.4), 108.9(2.7)	[17]
9	20.1	Hyperin	[M–H] [−] : 462.9 [M+Na] ⁺ : 487.1	464	300.7 (100), 178.7(4.7), 150.7(5.7)	[17,20]
10	20.3	Procyanidin B3	[M–H] [−] : 577.1 [M+H] ⁺ : 579.1	578	559.0(4.8), 450.9(15.9), 425.0 (100), 407.0 (98.4), 288.9(22.8), 286.9(16.1)	[19]
10	20.3	Isoquercetin	[M–H] [−] : 462.9 [M+Na] ⁺ : 487.1	464	301 (100), 178.7(4.9), 150.7(4.0)	[17,20]
11	21.3	A-type Procyanidin trimer	[M–H] [−] : 863.3 [M+H] ⁺ : 865.2	864	575.0 (100), 711.1(53.4), 699.1(42.9), 693.1(36.7), 576.1(25.4), 713.1(24.4), 821.2(23.9), 803.2(20.1)	[19]
12	23.1	(Epi)afzelechin- (Epi)catechin	[M–H] [−] : 561.1 [M+H] ⁺ : 563.2	562	270.8 (100), 451.0(70.4), 423.0(62.8), 435.0(61.2), 408.9(49.3), 298.8(38.7), 288.9(31.8), 324.9(22.7), 282.9(21), 258.8(19.5),	[18]
13	23.3	Procyanidin dimer A1	[M–H] [−] : 575.1 [M+H] ⁺ : 577.1	576	423 (100), 449(85.6), 539(42.4), 284.9(35.2), 407(29.1), 423.9(26.1), 288.9(25.1)	[19]
14	25.6	Emarginin C	[M–H] [−] : 373.1 [M+Na] ⁺ : 397.1	374	210.7 (100), 373(8.6)	[5]
15	28.0	Quercetin with two glycosides	[M–H] [−] : 591.1 [M+H] ⁺ : 593.2	592	547.0(17.4), 438.9 (100), 300.9(52.9), 288.9(64.6), 256.8(17.8), 214.7(29.9), 212.7(10.0)	[18,20]
16	35.1	Quercetin	[M–H] [−] : 300.9 [M+H] ⁺ : 302.9	302	178.7 (100), 150.7(92.4), 254.9(38.4), 272.8(29), 256.7(10.7)	[17,20]
17	38.4	Lupeol	[M–H] [−] : 425.0 [M+H] ⁺ : 427.1	426	407(30.8), 363.3 (100), 300.9(17.8), 288(66.6), 256.8(10.3), 244.8(17.5), 214.8(19.1)	[21,22]; this study
18	39.7	β-Amyrin	[M–H] [−] : 425.0 [M+H] ⁺ : 427.1	426	407(19.3), 389(10.9), 363(80.5), 314.9 (100), 288.8(9.1), 270.9(14.4), 240.7(15.0), 228.8(21.5), 204.7 (11.6), 176.7(10.0)	[21,22]; this study
19	40.3	α-Amyrin	[M–H] [−] : 425.1 [M+H] ⁺ : 427.1	426	407(50.5), 389(22.3), 381.0(14.2), 362.9(94.3), 314.9 (100), 288.8(14.3), 270.9(14.3), 240.8(18.8), 228.8(28.2), 204.7 (13.0)	[21,22]; this study

Table 2. Cont.

No.	R.T. (min)	Assigned Identity	Mass	M.W.	Negative ESI-MS ⁿ <i>m/z</i> (% Base Peak)	Reference
20	40.8	Friedelin	[M–H] [−] : 425.1 [M+H] ⁺ : 427.1	426	407(20.5), 363.3 (100), 300.9(19.9), 288(65.4), 256.8(15), 244.8(14.4), 214.8(21.5)	[21–23]
21	42.9	Unknown	[M–H] [−] : 675.4 [M+Na] ⁺ : 699.4	676	396.9 (100), 415.0 (50.4), 234.8 (10.5), 397.8 (9.2), 304.8 (5.8), 286.9 (5.6)	
22	44.7	Unknown	[M–H] [−] : 677.4 [M+Na] ⁺ : 701.4	678	397.0 (100), 415.0 (34.4), 234.7 (9.4), 304.9 (7.3), 286.8 (6.4)	

2.3. Isolation and Identification of Chemical Components from EA Fraction of *V. emarginatum* Extraction

The anti-proliferative and anti-bacterial constituents of the most effective fractions are in the EA portion. The EA-soluble fraction (4.59 g) was applied to silica gel column chromatography using a gradient solvent system (n-hexane/EA/MeOH). As shown in Figure 4, collected fractions were checked by TLC and combined into 20 main subfractions (EA-1~EA-20). Fraction EA-3, EA-6, EA-17, EA-18 and EA-19 were isolated by using column chromatography and HPLC to obtain 11 pure compounds: Compound 1 (2.3 mg), 2 (233.6 mg), 3 (11.4 mg), 4 (1.4 mg), 5 (2.2 mg), 6 (14.5 mg), 7 (1.1 mg), 8 (22.6 mg), 9 (13.6 mg), 10 (3.0 mg) and 11 (1.2 mg). Purified compounds were applied to spectroscopic identification by using ¹H-NMR, ¹³C-NMR and mass analysis. All of the carbon and proton signals were assigned based on the correlation of heteronuclear multiple bond correlation (HMBC) and heteronuclear multiple-quantum (HMQC). The chemical structures of isolated phenolic (1), flavonoids (2–3, 8), procyanidins (4–5), flavonoid glycosides (6–7), and triterpenoids (9–11) were illustrated in Figure 5.




Figure 4. Purification flow chart of chemical constituents isolated from root nodules of *V. emarginatum*.




Figure 5. Chemical structures of isolated compounds 1–11.

The NMR spectrums and mass data of compounds (1–11) from the root nodules of *V. emarginatum* were compared with previous reports. Eleven chemicals were identified as protocatechuic acid (1) [25], epicatechin (2) [24,25], catechin (3) [24,25], procyanidin B3 (4) [24,26,27], procyanidin A1 (5) [24,26,27], hyperin (6) [28], isoquercetin (7) [29], quercetin (8) [24,30], lupeol (9) [30,31], β -amyrin (10) [31,32], and α -amyrin (11) [31], respectively (Figure 5).

2.4. Anti-Proliferative Activity of Isolated Compounds

Anti-proliferative activities of Compounds 1–11 were determined by measuring the IC₅₀ of hepatocellular carcinoma (HepG2), lung carcinoma (A549) and gastric adenocarcinoma (AGS). As shown in Table 3, none of the phenolic acid and flavonoids have the anti-proliferative activity. Both of the procyanidins (Compound 4 and 5) exhibited anti-proliferative activity against HepG2 at IC₅₀ values between 38.4 and 41.1 μ M. The AGS cells were moderately inhibited by procyanidins at IC₅₀ values between 79.4 and 83.8 μ M. In addition, Compound 7 displayed the strongest anti-proliferative activity against the HepG2, A549, and AGS cell proliferation at 18.7, 24.6 and 68.5 μ M, respectively. Among the triterpenoids (Compound 9–11), only Compound 9 showed the inhibitory activity against all the tested tumor cell lines at IC₅₀ values between 72.9 and 146.8 μ M.

Table 3. Anti-proliferative activities of isolated compounds on tumor cell lines.

Compounds	Anti-Proliferative Activity, IC ₅₀ (μM)		
	HepG2 2.2.15	A549	AGS
1	>200	>200	>200
2	>200	>200	>200
3	>200	>200	>200
4	41.1 ± 1.3	>200	79.4 ± 2.3
5	38.4 ± 1.4	>200	83.8 ± 3.6
6	>200	>200	>200
7	18.7 ± 0.9	24.6 ± 0.6	68.5 ± 4.5
8	64.0 ± 1.4	>200	82.2 ± 4.6
9	81.7 ± 1.7	146.8 ± 5.8	72.9 ± 1.7
10	>200	174.2 ± 6.1	>200
11	>200	>200	>200
EGCG	N.D. *	91.9 ± 1.8	N.D.
5-fluorouracil	62.0 ± 1.1	N.D.	N.D.
Doxorubicin	N.D.	N.D.	11.0 ± 0.6

* N.D.: not determined; 1: protocatechuic acid; 2: epicatechin; 3: catechin; 4: procyanidin B3; 5: procyanidin A1; 6: hyperin; 7: isoquercetin; 8: quercetin; 9: lupeol; 10: beta-amyrin; 11: alpha-amyrin.

2.5. Anti-Bacterial Activity of Isolated Compounds

The minimum inhibitory concentration (MIC) method was applied for an anti-bacterial activity exploration of isolated compounds. As shown in Table 4, only procyanidins dimer (Compound 4 and 5) and one flavonoid glycoside (Compound 7) displayed moderate anti-bacterial activity against *S. aureus*. Most of the triterpenoids displayed non-anti-bacterial activities against all tested pathogens, except for Compound 7, which showed moderate activity against *E. faecalis* at a concentration of 64 μg/mL. In addition, only Compound 5 showed moderate antimicrobial activities against *B. cereus* and *L. monocytogenes*. None of the isolated compounds had anti-bacterial activities against *S. enterica* in this study.

Table 4. The minimum inhibitory concentration (MIC) value of isolated compounds and antibiotics for different bacterial pathogens.

Compounds	MIC (μg/mL)						
	Bacterial Pathogens						
	<i>S. aureus</i>	<i>E. faecalis</i>	<i>L. monocytogenes</i>	<i>B. cereus</i>	<i>E. coli</i>	<i>S. enterica</i>	<i>P. aeruginosa</i>
Ap *	8	2	1	64	4	2	256
Tet	4	2	2	2	1	8	16
1	>128	>128	>128	>128	>128	>128	>128
2	>128	>128	>128	>128	>128	>128	>128
3	>128	>128	>128	>128	>128	>128	>128
4	64	>128	>128	>128	>128	>128	>128
5	64	>128	64	64	>128	>128	>128
6	>128	128	>128	128	>128	>128	128
7	64	>128	>128	128	128	>128	128
8	128	>128	128	>128	>128	>128	>128
9	>128	64	>128	>128	>128	>128	>128
10	>128	128	>128	128	>128	>128	>128
11	>128	>128	>128	>128	>128	>128	>128

* Ap: ampicillin; Tet: tetracycline; 1: protocatechuic acid; 2: epicatechin; 3: catechin; 4: procyanidin B3; 5: procyanidin A1 c; 6: hyperin; 7: isoquercetin; 8: quercetin; 9: lupeol; 10: beta-amyrin; 11: alpha-amyrin.

3. Discussion

In this study, the biological activities of different chemical fractions from *V. emarginatum* methanol extracts were evaluated. The results indicate that the EA fraction showed pronounced anti-cancer and anti-bacterial activity, and its phytochemical profile was fur-

ther analyzed by LC-ESI-MS/MS. Twenty-two peaks were identified as five flavonoids, three flavonol glycosides, six procyanidins, one phenolic acid, five triterpenoids and two unknown chemicals. LC-ESI-MS/MS with negative ion detection had been dramatically used for tentative identification of a variety of phenolic compounds in fruits [3,17,19], flowers [20], and traditional herb medicine [18,22]. LC-ESI-MS/MS is a great analytical tool because of its high selectivity for analyzing complex components in plants. Moreover, negative ESI-MS provided a qualitative analysis useful in the screening of phenolics, flavonoids, and procyanidins. It provides simple MS/MS spectra in which it was possible to observe the loss of units more easily in contrast to positive ESI-MS fragmentation with Na^+ adducts [18,33].

Triterpenoids have been analyzed for a long period and are still widely detected and identified using gas chromatography mass spectrometry (GC-MS) [34,35]. Most triterpenoids are lacking a chromophore group, for example, neutral triterpenes have only one hydroxyl group on their structure, such as lupeol and amyrin, which are not easily ionized by ESI. Although liquid chromatography is more suitable for non-volatile chemicals, the triterpenoids founded in this study can be identified by both negative and positive LC-ESI-MS/MS and structurally identified by NMR.

Previously, the new flavonoid emarginin C, which was isolated from the whole plants of *V. emarginatum*, exhibited anti-inflammatory activity with an IC_{50} value of 27.99 μM [5]. In addition, the triterpenoid coumaroyl and feruloyl esters exhibited strong cytotoxicity against PC-3 prostate cancer cells, with 85.6–90.2% inhibition at 10.0 $\mu\text{g}/\text{mL}$ [9]. In this study, the anti-proliferative activities of isolated compounds were determined by measuring the IC_{50} of hepatocellular carcinoma (HepG2), lung carcinoma (A549) and gastric adenocarcinoma (AGS). The results indicate that isolated procyanidin B3 and A1 are the promising lead compounds of *V. emarginatum* for anti-proliferative activities. Other procyanidins, such as procyanidin A2, showed an IC_{50} value of 62.19 $\mu\text{g}/\text{mL}$ on human hepatoma HepG2 cells [36]. All of these findings suggest that procyanidins may act as anti-proliferative agents in human hepatoma cells.

Vaccinium species are perennial and low-growing herbs found in the temperate climate regions. The berries of *Vaccinium* contain abundant flavonoids, including flavonol glycosides, anthocyanins, flavan3-ols, and procyanidins [37]. Among flavonoids, procyanins are the greatest contributors to the antioxidant capacity in the genus *Vaccinium* [38]. Most of the wild and cultivated cranberries contain both A- and B-type procyanidins. In this study, the EA fraction of *V. emarginatum* methanol extract also contained both dimeric and trimeric procyanidins. Peak 2, 4 and 10 were identified as B-type procyanidins B1, B2 and B3 according to the data of retention time, mass spectrum and MS/MS ion [19,24]. In addition, A-type procyanidins, including dimer A1 and three unknown trimers, were also found in this study. The procyanidin trimer with more OH groups in one benzene unit may increase the antioxidant activity significantly [26]. Flavonoids with a dihydroxy structure on the B ring have been shown to be effective in biological function [39]. In the group of flavonoids, this catechol unit is found in catechins, epicatechin, quercetin, and procyanidins. All of these flavonoids were also found in the root nodule of *V. emarginatum*, indicating that not only the berries but also the root nodule of *V. emarginatum* can be a great source of procyanidins.

In this study, the anti-bacterial activities of isolated compounds were also tested against seven bacterial pathogens by minimum inhibitory concentration (MIC) methods. The determination of MIC against Gram-positive bacteria gave a value of 64 $\mu\text{g}/\text{mL}$ for procyanidin B3 (4) and A1 (5). Previous reports revealed a moderate for certain procyanidins against *Bacillus cereus*, *Klebsiella pneumoniae*, *Proteus vulgaris* and *Streptococcus pyogenes* at concentrations below 100 $\mu\text{g}/\text{mL}$ [40]. In addition, procyanidin B2, which was also found in the EA fraction by LC-ESI-MS/MS analysis in this study, generated anti-bacterial activity against *S. aureus* at an MIC value of 100 $\mu\text{g}/\text{mL}$ [41]. All of these results indicate that procyanidin dimers displayed moderate antimicrobial activity against certain pathogens. As a potential anti-cancer agent, procyanidin has been shown to inhibit

the proliferation of various cancer cells [26,42]. Moreover, several assays demonstrate potential biological functions of procyanidins, including antioxidant, radical-scavenging properties [26], and enzyme inhibiting [43] has also been reported. It is suggested that procyanidin might be the valuable group of *V. emarginatum* as a source of promising compounds for the development of future pharmacological applications.

4. Materials and Methods

4.1. General Information

Column chromatography (CC) was carried out by using Sephadex LH-20 (Amersham Pharmacia Biotech, Uppsala, Sweden), LiChroprep RP-18 (Merck, Darmstadt, Germany), XAD-2 (Sigma-Aldrich, St. Louis, MO, USA), XAD-7 (Sigma-Aldrich, St. Louis, MO, USA), Toyoppearl HW-40F (Tosoh Bioscience, Tokyo, Japan), and silica gel 60 (Merck, 230–400 mesh, Darmstadt, Germany). Silica gel plates (Merck, F254, 0.25 mm) and RP-18 plates (Merck, F254s, 0.25 mm) were used for thin-layer chromatography (TLC) analyses. Purification was processing with a semi-preparative reversed-phase column (Merck, Hibar Purospher RP-18e, 5 μ m, 250 \times 10 mm) on the Hitachi HPLC (L-2130 pump with a L-2420 UV-vis detector).

The NMR spectra data were measured on an Avance NEO 400 spectrometer (Bruker Daltonics Inc., Billerica, MA, USA) and an Agilent Technologies DD2 600 spectrometer (Agilent, Santa Clara, CA, USA). ESI-MS spectra were performed on a Bruker Daltonics Esquire HCT spectrometer (Bruker Daltonics Inc., Billerica, MA, USA).

4.2. Plant Materials

The root nodules of *Vaccinium emarginatum* Hayata were collected from cloud forests in Jan 2010 and Feb 2010, at the Dasyueshan site (24°14'13.43" N, 120°57'10.86" E at 1939 m asl.; annual rainfall: 2000–3000 mm) in Taiwan. *V. emarginatum* was identified by the Key Laboratory of the High Altitude Experimental Station in the Taiwan Endemic Species Research Institute. The voucher specimen (2010-0120-Wang) was preserved in the Lab of Chemical Ecology, Research Center for Biodiversity, China Medical University.

4.3. Liquid Chromatography-Electrospray Ionization/Tandem Mass Spectrometry (LC-ESI-MS/MS)

LC mass analysis for the chemical components in the EA fraction was applied to LC-ESI-MS/MS) analysis (Esquire HCT, Bruker Daltonics, Billerica MA, USA). At a flow rate of 0.25 mL/min, the Atlantis T3 RP-18 column (150 \times 2.1 mm; 3 μ m; Waters, Milford, MA, USA) was eluted with Buffer A (distilled water/acetonitrile/formic acid; 95/5/0.1, v/v/v) and Buffer B (acetonitrile/formic acid; 100/0.1, v/v) at 25 °C. Elution started initially with 100% Buffer A, followed by a linear increase in Buffer B to 10% from 0 to 5 min, and maintained in 10% Buffer B for another 5 min. A secondary linear increase in Buffer B to 20% was carried out from 10 to 20 min and maintained in 20% Buffer B for another 10 min. From 30 to 35 min, the column was further eluted with a third linear increase in Buffer B to 60% and maintained for another 5 min. A final linear increasing of Buffer B was carried out from 60% to 95% and maintained for 5 min from 40 to 45 min. The column was finally equilibrated with Buffer A for another 10 min. The ion source temperature is maintained at 100 °C and the dry temperature is 365 °C. The flow rate of N₂ desolvation gas is sustained at 12 L/min. Product ion scans for mass were accomplished by low-energy collision (20 eV) using argon as the collision gas. MS spectrum data of both positive and negative ionization mode were collected. All data were analyzed by Bruker Daltonics Data software (version 4.0).

4.4. Isolation and Identification of Chemical Constitutes from *V. emarginatum* Extract

Six kilograms of *V. emarginatum* root nodules was air-dried (630 g) and extracted with methanol thrice following the standard extraction procedures. The methanolic extract was concentrated to gain 37.3 g dry residue and then partitioned by dichloromethane, ethyl

acetate, butanol with H₂O to the obtained portion of DCM (5.90 g), EA (8.59 g), BuOH (7.28 g), and an aqueous layer (14.86 g), sequentially.

Bioassay-guided chromatography was carried out for anti-proliferative and anti-bacterial compound isolation (Figure 2; Table 1). The EA portion was subjected to a silica gel column in gradient elution of mixture solvent composed of hexane-ethyl acetate and led to 20 fractions. Fraction EA-3 (1.08 g) was separated via silica gel column with a hexane-ethyl acetate mixture as the eluent to obtain 10 subfractions (EA-3-1~EA-3-10) and Compound 9 (13.6 mg), 10 (3.0 mg) and 11 (1.2 mg) were purified from subfraction EA-3-5 and EA-3-6. Fraction EA-6 was further fractionated by another silica gel column with a hexane-ethyl acetate mixture (5:1) to give 12 subfractions. Compound 8 was isolated from fraction 6-5-7 by reverse-phase C-18 chromatography in gradient elution of MeOH–H₂O (60% to 100%). Compounds 4 (1.4 mg), 5 (2.2 mg), 6 (14.5 mg) and 7 (1.1 mg) were isolated from the effective fractions 15-2-12, 15-2-13 and 15-2-14 by reverse-phase C-18 chromatography in gradient elution of MeOH–H₂O (40% to 100%). Compound 2 was crystallized from subfraction EA-16 fractionated by silica gel column with a hexane-ethyl acetate mixture (1:8). In addition, Compound 1 (2.3 mg) and 3 (11.4 mg) were isolated from the fraction of EA-17 (1.23 g), by XAD-7, HW-40F and RP-18 chromatography in gradient elution of MeOH–H₂O (10% to 100%). Purified compounds were subjected to spectroscopic identification using ¹H-NMR and ¹³C-NMR (Agilent Technologies DD2 600) and Mass (Bruker Daltonics Esquire HCT). All isolated compounds were identified by comparison of spectra data with literature reported previously. Detail structure elucidation of isolated compounds in this study was described in Supplementary Materials.

Protocatechuic acid (1). White amorphous powder; ESI-MS: [M–H][−], 152.7 *m/z*, (calcd for C₇H₅O₄: 153.1). ¹H-NMR (400 MHz, CD₃OD): δH 7.42 (1H, d, *J* = 1.8 Hz, H-2), 7.40 (1H, dd, *J* = 7.8, 2.0 Hz, H-5), 6.79 (1H, d, *J* = 8.0 Hz, H-6).

Epicatechin (2): White amorphous powder; ESI-MS: [M–H][−], 288.8 *m/z*, (calcd for C₁₅H₁₃O₆: 289.2); ¹H-NMR (400 MHz, CD₃OD): δH 6.96 (1H, d, *J* = 1.6 Hz, H-10), 6.76 (1H, d, *J* = 8.8 Hz, H-14), 6.74 (1H, dd, *J* = 2.0, 8.8 Hz, H-13), 5.93 (1H, d, *J* = 2.0 Hz, H-8), 5.90 (1H, d, *J* = 2.4 Hz, H-6), 4.80 (1H, s, H-2), 4.15 (1H, d, *J* = 3.2, H-3), 2.86 (1H, dd, *J* = 8.8, 16.8 Hz, H-4 ax), 2.73 (1H, dd, *J* = 2.8, 16.8 Hz, H-4 eq); ¹³C-NMR (150 MHz, CD₃OD): δC 157.9 (C-7), 157.6 (C-5), 157.3 (C-8a), 145.8 (C-11), 145.7 (C-12), 132.2 (C-9), 119.3 (C-13), 115.8 (C-14), 115.2 (C10), 100.0 (C-4a), 96.3 (C-6), 95.8 (C-8), 79.8 (C-2), 67.4 (C-3), 29.2 (C-4).

Catechin (3): Yellow powder, ESI-MS: [M–H][−], 288.8 *m/z*, (calcd for C₁₅H₁₃O₆: 289.2); ¹H-NMR (400 MHz, CD₃OD): δH 6.83 (1H, d, *J* = 1.6 Hz, H-10), 6.76 (1H, d, *J* = 8.1 Hz, H-14), 6.70 (1H, dd, *J* = 1.8, 8.1 Hz, H-13), 5.84 (1H, d, *J* = 2.2 Hz, H-8), 5.91 (1H, d, *J* = 2.2 Hz, H-6), 4.55 (1H, dd, *J* = 7.5, H-2), 3.96 (1H, m, H-3), 2.83 (1H, dd, *J* = 5.4, 16.1 Hz, H-4), 2.49 (1H, dd, *J* = 8.1, 16.1 Hz, H-4); ¹³C-NMR (150 MHz, CD₃OD): δC 157.7 (C-7), 157.5 (C-5), 156.8 (C-8a), 146.2 (C-11), 146.2 (C-12), 132.1 (C-9), 120.0 (C-13), 116.0 (C-14), 115.2 (C10), 100.8 (C-4a), 96.3 (C-6), 95.5 (C-8), 82.8 (C-2), 68.8 (C-3), 28.5 (C-4).

Procyanidin B3 (4): White amorphous powder; ESI-MS: [M–H][−], 577.1 *m/z*, (calcd for C₃₀H₂₅O₁₂: 577.5); ¹H-NMR (CD₃OD, 400 MHz): δH 6.94 (1H, d, *J* = 1.8 Hz, H-10), 6.76 (1H, dd, *J* = 6.0, 1.8 Hz, H-14), 6.67 (1H, d, *J* = 7.8 Hz, H-13), 5.87 (1H, d, *J* = 2.4 Hz, H-6), 5.78 (1H, d, *J* = 2.4 Hz, H-8), 4.36 (1H, d, *J* = 5.4 Hz, H-3), 4.39 (1H, d, *J* = 7.8 Hz, H-4), 4.24 (1H, d, *J* = 7.8 Hz, H-2), 4.53 (1H, d, *J* = 7.2 Hz, H-2'), 3.77 (1H, m H-3'), 2.48 (1H, dd, *J* = 16.2, 7.8 Hz, H-4'α), 2.76 (1H, dd, *J* = 16.2, 5.4 Hz, H-4'β), 6.57 (1H, d, *J* = 1.8 Hz, H-10'), 6.82 (1H, dd, *J* = 6.0, 2.4 Hz, H-14'), 6.65 (1H, d, *J* = 8.4 Hz, H-13'), 6.06 (1H, s, H-6'); ¹³C-NMR (CD₃OD, 150 MHz): δC 84.0 (C-2), 73.6 (C-3), 38.5 (C-4), 107.1 (C-4a), 157.2 (C-5), 97.5 (C-6), 157.4 (C-7), 96.2 (C-8), 158.6 (C-8a), 132.4 (C-9), 116.1 (C-10), 146.1 (C-11), 146.3 (C-12), 116.0 (C-13), 121.0 (C-14), 82.9 (C-2'), 68.5 (C-3'), 28.4 (C-4'), 100.4 (C-4'a), 154.9 (C-5'), 95.5 (C-6'), 155.7 (C-7'), 108.3 (C-8'), 155.6 (C-8'a), 132.1 (C-9'), 115.1 (C-10'), 146.1 (C-11'), 146.3 (C-12'), 115.9 (C-13'), 120.1 (C-14').

Procyanidin A1 (5): White amorphous powder; ESI-MS *m/z* 575.1 [M–H][−] (Calcd for C₃₀H₂₃O₁₂: 575.5). ¹H-NMR (CD₃OD, 600 MHz) δH 4.06 (1H, d, *J* = 4.2 Hz, H-3), 4.23 (1H, d, *J* = 3.6 Hz, H-4), 5.95 (1H, d, *J* = 2.4 Hz, H-6), 6.06 (1H, d, *J* = 2.4 Hz, H-8), 7.12 (1H, d,

$J = 1.8$ Hz H-10), 6.81 (1H, d, $J = 8.4$ Hz, H-13), 7.01 (1H, dd, $J = 8.4, 2.4$ Hz, H-14), 4.72 (1H, d, $J = 7.8$ Hz H-2'), 4.14 (1H, m, H-3'), 2.57 (1H, dd, $J = 16.2, 8.4$ Hz, H-4' α), 2.94 (1H, dd, $J = 16.2, 5.4$ Hz, H-4' β), 6.08 (1H, s, H-6'), 6.91 (1H, s, H-10'), 6.81 (1H, s, H-13'), 6.81 (1H, d, $J = 8.4$ Hz, H-14'); $^{13}\text{C-NMR}$ (CD_3OD , 150 MHz) δC 100.3 (C-2), 67.8 (C-3), 29.2 (C-4), 104.0 (C-4a), 156.8 (C-5), 98.1 (C-6), 158.1 (C-7), 96.5 (C-8), 154.2 (8a), 132.3 (C-9), 115.6 (C-10), 146.8 (C-11), 145.6 (C-12), 116.3 (C-13), 119.8 (C-14), 84.5 (C-2'), 68.1 (C-3'), 29.0 (C-4'), 103.1 (C-4'a), 156.1 (C-5'), 96.5 (C-6'), 152.2 (C-7'), 106.8 (C-8'), 151.4 (C-8'a), 130.5 (C-9'), 115.7 (C-10'), 146.8 (C-11'), 146.3 (C-12'), 115.7 (C-13'), 120.7 (C-14').

Hyperin (6): Amorphous yellow powder; ESI-MS m/z 462.9 $[\text{M-H}]^-$ (Calcd for $\text{C}_{21}\text{H}_{19}\text{O}_{12}$: 463.3). $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): 7.66 (2H, dd, $J = 2.2, 8.4$ Hz, H-6'), 7.53 (1H, d, $J = 2.4$ Hz, H-2'), 6.82 (1H, d, $J = 8.4$ Hz, H-5'), 6.40 (1H, d, $J = 2.0$ Hz, H-8), 6.20 (1H, d, $J = 2.0$ Hz, H-6), 5.37 (1H, d, $J = 7.6$ Hz, gatactosyl H-I''); $^{13}\text{C-NMR}$ (DMSO- d_6 , 100 MHz): δC 177.7 (C4), 164.4 (C-7), 161.4 (C-5), 156.5 (C-2, C-9), 148.7 (C-4'), 145.0 (C-3'), 133.7 (C-3), 122.2 (C-6'), 121.3 (C-1'), 116.2 (C-5'), 115.4 (C-2'), 104.1 (C-10), 102.1 (C-1''), 98.9 (C-6), 93.7 (C-8), 76.1 (C-5''), 73.4 (C-3''), 71.4 (C-2''), 68.2 (C-4''), 60.4 (C-6'').

Isoquercetin (Quercetin-3-O-D-glucopyranoside) (7): Amorphous yellow powder, ESI-MS m/z 463.2 $[\text{M-H}]^-$ (Calcd for $\text{C}_{21}\text{H}_{19}\text{O}_{12}$: 463.3). $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δH 7.58 (2H, d, $J = 8.8$ Hz, H-2' and H-6'), 6.85 (2H, d, $J = 8.8$ Hz, H-5'), 6.36 (1H, d, $J = 2.0$ Hz, H-8), 6.17 (1H, d, $J = 2.0$ Hz, H-6), 5.25 (1H, d, $J = 7.2$ Hz, glucosyl H-1''). $^{13}\text{C-NMR}$ (DMSO- d_6 , 100 MHz): δC 177.6 (C-4), 164.5 (C-7), 161.3 (C-5), 156.5 (C-2), 156.3 (C-9), 148.6 (C-4'), 144.9 (C-3'), 133.5 (C-3), 121.7 (C-6'), 121.2 (C-1'), 116.3 (C-5'), 115.3 (C-2'), 104.1 (C-10), 101.0 (C-1''), 98.9 (C-6), 93.7 (C-8), 77.6 (C-5''), 76.6 (C-3''), 74.2 (C-2''), 70.0 (C-4''), 61.1 (C-6'').

Quercetin (8): Amorphous yellow powder, ESI-MS m/z 301.1 $[\text{M-H}]^-$ (Calcd for $\text{C}_{15}\text{H}_9\text{O}_7$: 301.2). $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δH 7.72 (1H, d, $J = 2.0$ Hz, H-2'), 7.62 (1H, dd, $J = 2.0, 8.4$ Hz, H-6'), 6.87 (1H, d, $J = 8.4$ Hz, H-5'), 6.37 (1H, d, $J = 1.6$ Hz, H-8), 6.17 (1H, d, $J = 2.0$ Hz, H-6); $^{13}\text{C-NMR}$ (DMSO- d_6 , 100 MHz): δC 176.4 (C4), 164.4 (C-7), 161.1 (C-5), 157.0 (C-9), 148.2 (C-4'), 147.4 (C-2), 145.5 (C-3'), 136.1 (C-3), 122.5 (C-1'), 120.5 (C-6'), 116.1 (C-5'), 115.4 (C-2'), 103.4 (C-10), 98.6 (C-6), 93.8 (C-8).

Lupeol (9): White amorphous powder; ESI-MS m/z 425.0 $[\text{M-H}]^-$ (Calcd for $\text{C}_{30}\text{H}_{49}\text{O}$: 425.7); $^1\text{H-NMR}$ spectrum (600 MHz, CDCl_3): δH 3.20 (1H, m, H-3), 0.68 (1H, d, $J = 9.6$ Hz, H-5), 2.38 (1H, m, H-19), 4.69 (1H, brs, H-29), 4.57 (1H, brs, H-29), 1.03, 0.97, 0.95, 0.83, 0.79, 0.76 (Me-26, Me-27, Me-23, Me-25, Me-28, Me-24), 1.68 (3H, s, Me-30). $^{13}\text{C-NMR}$ spectrum (150 MHz, CDCl_3): δC : 150.9 (C-20), 109.3 (C-29), 78.9 (C-3), 55.2 (C-5), 50.3 (C-9), 48.2 (C-18), 47.9 (C-19), 42.9 (C-17), 42.7 (C-14), 40.7 (C-8), 39.9 (C-22), 38.8 (C-13), 38.6 (C-4), 38.0 (C-1), 37.1 (C-10), 35.5 (C-16), 34.2 (C-7), 25.0 (C-2), 20.8 (C-11), 27.4 (C-12), 27.9 (C-15), 29.8 (C-21), 29.6 (C-23), 19.2 (C-30), 18.2 (C-6), 17.9 (C-28), 16.1 (C-25), 15.9 (C-26), 15.3 (C-24), 14.5 (C-27).

β -Amyrin (10): Colorless solid; ESI-MS m/z 425.1 $[\text{M-H}]^-$ (Calcd for $\text{C}_{30}\text{H}_{49}\text{O}$: 425.7); $^1\text{H-NMR}$ spectrum (600 MHz, CDCl_3): δH 3.23 (1H, dd, $J = 10.4, 4.8$ Hz, H-3), 0.74 (1H, dd, $J = 12.0, 1.2$ Hz, H-5), 1.56 (1H, dd, $J = 7.8, 1.8$ Hz, H-9), 5.18 (1H, t, $J = 3.6$ Hz, H-12), 1.94 (1H, dd, $J = 14.4, 4.8$ Hz, H-18), 1.13 (3H, s, Me-27), 0.99, 0.96, 0.93, 0.88, 0.87, 0.83, 0.79 (Me-23, Me-26, Me-25, Me-29, Me-30, Me-28, Me-24). $^{13}\text{C-NMR}$ spectrum (150 MHz, CDCl_3): δC : 145.2 (C-13), 121.7 (C-12), 79.0 (C-3), 55.1 (C-5), 47.6 (C-9), 47.2 (C-18), 46.8 (C-19), 41.7 (C-14), 39.7 (C-8), 38.7 (C-4), 38.5 (C-1), 37.1 (C-22), 36.9 (C-10), 34.7 (C-21), 33.3 (C-29), 32.6 (C-7), 32.4 (C-17), 31.1 (C-20), 28.3 (C-28), 28.0 (C-23), 27.2 (C-2), 26.9 (C-16), 26.1 (C-15), 25.9 (C-27), 23.6 (C-30), 23.5 (C-11), 18.3 (C-6), 16.7 (C-26), 15.5 (C-24), 15.5 (C-25).

α -Amyrin (11): Colorless solid; ESI-MS m/z 425.0 $[\text{M-H}]^-$ (Calcd for $\text{C}_{30}\text{H}_{49}\text{O}$: 425.7); $^1\text{H-NMR}$ spectrum (600 MHz, CDCl_3): δH 3.30 (1H, dd, $J = 11.4, 5.4$ Hz, H-3), 0.74 (1H, dd, $J = 12.0, 1.2$ Hz, H-5), 5.13 (1H, t, $J = 3.6$ Hz, H-12), 1.99 (2H, td, $J = 13.5, 4.8$ Hz, H-15), 1.84 (2H, td, $J = 13.6, 4.9$ Hz, H-16), 1.07, 1.01, 1.00, 0.95, 0.80, 0.79 (Me-27, Me-26, Me-23, Me-24, Me-28, Me-25), 0.78 (3H, d, $J = 4.8$ Hz, Me-29), 0.92 (3H, d, $J = 6.0$ Hz, Me-30). $^{13}\text{C-NMR}$ spectrum (150 MHz, CDCl_3): δC : 139.5 (C-13), 124.4 (C-12), 38.7 (C-1), 28.0 (C-2), 79.0 (C-3), 59.0 (C-18), 55.1 (C-5), 47.7 (C-9), 42.0 (C-14), 41.5 (C-22), 39.9 (C-8), 39.6 (C-19), 39.6 (C-20),

38.7 (C-4), 36.8 (C-10), 33.7 (C-17), 32.9 (C-7), 31.2 (C-21), 28.7 (C-28), 28.1 (C-23), 27.2 (C-15), 26.6 (C-16), 23.3 (C-11), 23.2 (C-27), 21.4 (C-30), 18.3 (C-6), 17.4 (C-29), 16.8 (C-26), 15.6 (C-24), 15.6 (C-25).

4.5. Anti-Bacterial Assay

The disc diffusion method was applied to anti-bacterial-guided fractionation. The chemical fractions were dissolved in DMSO at a concentration of 100 µg/µL. According to the standard protocol (Clinical and Laboratory Standards Institute, CLSI) [44], 10 µL of dried extracts was applied to paper discs (6 mm in diameter) and placed on Mueller Hinton agar plates, which were inoculated with overnight-cultured pathogens. The plates were incubated at 37 °C for 18 h. The diameters of the inhibition zones were measured within 24 h, and discs containing DMSO and antibiotics were served as a negative and positive control. At least three independent determinations were repeated.

The anti-bacterial activity of purified compounds was conducted by the minimum inhibitory concentration (MIC) method. According to the guidelines of the CLSI [45], the MIC values were determined by the broth micro-dilution method. Briefly, all bacterial strains were cultured on nutrient agar and incubated at 37 °C for 24 h. Bacteria were suspended in 0.85% NaCl solution and diluted to give an inoculum with a final density of 5×10^5 cfu/mL. Isolated compounds were dissolved in DMSO at a final concentration of 2560 µg/mL. Two-fold dilutions were made serially in a concentration range from 0.5 to 128 µg/mL. In each 96-well plate, all of the wells were calculated for bacterial growth by spectrophotometer at 590 nm. The lowest concentration that inhibited the growth of the respective pathogen was defined as the MIC value. The antibiotics (ampicillin and tetracycline) were used as a positive control. All tests were carried out in triplicate.

4.6. Anti-Proliferative Assay

Anti-proliferative assay was determined against HepG2 2.2.15 (human hepatocellular carcinoma cells) and A549 cells (human lung adenocarcinoma cell line) using the MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay (Promega, USA). Briefly, HepG2 2.2.15 and A549 cells were treated with 2-fold serial dilutions of the tested compounds ranging from 0.19 to 200 µM for 3 days. After incubation, the medium from the wells was removed carefully. To each well, 50 µL of serum-free medium and 50 µL of MTT solution (5 mg/mL in PBS) were added. The plate was incubated for 3 hours in 37 °C incubator with 5% CO₂. After incubation, 150 µL MTT solution was added into each well and the plates were shaken on a shaker for 15 min. Mixing well by micropipette may be required to fully dissolve the MTT formazan. The presence of viable cells was visualized by the formation of formazan crystals in purple color. Plates were read at 570 nm for cytotoxicity assay within one hour.

The human gastric adenocarcinoma (AGS cell line) was cultured in RPMI-1640 medium supplemented with antibiotics (100 µg/mL of streptomycin and 100 U/mL of penicillin) and 10% FBS (fetal bovine serum). The AGS cell was treated with compounds ranging from 0.19 to 200 µM for 2 days. The trypan blue exclusion protocol was used for in vitro cytotoxicity assay. In brief, 40 µL of trypan blue was mixed with 10 µL of cell suspension and the numbers of dead cells (stained) and live cells (unstained) were counted using a hemocytometer. After treatment, the cell viability as the percentage of cell survival was recorded and the value of IC₅₀ was also calculated. All measurements were performed in triplicate, and epigallocatechin gallate (EGCG), 5-fluorouracil, and doxorubicin were used as the positive control.

5. Conclusions

In this study, twenty peaks of EA fraction from *V. emarginatum* extract were identified by LC-ESI-MS/MS analysis, and eleven of them were isolated and identified by NMR analysis. The ability of procyanidin B3, A1, isoquercetrin, quercetin and lupeol to inhibit

the tumor proliferative activity means that they have the potential to constitute a valuable group of therapeutic agents in the future.

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/ph14111098/s1>, Figures S1–S27 NMR spectral (1D or 2D for isolated compounds) and MS/MS data.

Author Contributions: H.-M.H., C.-Y.H. and C.-M.W. conceived the idea and performed experiments. G.-R.C., W.-Y.S., and C.-H.L. assisted in experiments and data analysis. C.-M.W. and C.-H.C. wrote, reviewed, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financially supported, in part, by research grants from the Ministry of Science and Technology (MOST 110-2313-B-415-001-MY2) in Taiwan awarded to C.-M.W., from Chang Bing Show Chwan Memorial Hospital (RD107034) awarded to C.-H.C., and from China Medical University Hsinchu Hospital (CMUHCH-DMR-110-013) awarded to H.-M.H.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: Technical assistance with chemical data analyses from Proteomics Research Core Laboratory, Office of Research & Development at China Medical University and Instrument Analysis Centers at the National Chung-Hsing University is greatly appreciated.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Debnath, S.C.; Goyal, J.C. In Vitro Propagation and Variation of Antioxidant Properties in Micropropagated Vaccinium Berry Plants—A Review. *Molecules* **2020**, *25*, 788. [[CrossRef](#)] [[PubMed](#)]
2. Deziel, B.A.; Patel, K.; Neto, C.; Gottschall-Pass, K.; Hurta, R.A. Proanthocyanidins from the American Cranberry (*Vaccinium macrocarpon*) inhibit matrix metalloproteinase-2 and matrix metalloproteinase-9 activity in human prostate cancer cells via alterations in multiple cellular signalling pathways. *J. Cell Biochem.* **2010**, *111*, 742–754. [[CrossRef](#)] [[PubMed](#)]
3. Esquivel-Alvarado, D.; Munoz-Arrieta, R.; Alfaro-Viquez, E.; Madrigal-Carballo, S.; Krueger, C.G.; Reed, J.D. Composition of Anthocyanins and Proanthocyanidins in Three Tropical *Vaccinium* Species from Costa Rica. *J. Agric. Food. Chem.* **2020**, *68*, 2872–2879. [[CrossRef](#)] [[PubMed](#)]
4. Kylli, P.; Nohynek, L.; Puupponen-Pimia, R.; Westerlund-Wikstrom, B.; Leppanen, T.; Welling, J.; Moilanen, E.; Heinonen, M. Lingonberry (*Vaccinium vitis-idaea*) and European cranberry (*Vaccinium microcarpon*) proanthocyanidins: Isolation, identification, and bioactivities. *J. Agric. Food Chem.* **2011**, *59*, 3373–3384. [[CrossRef](#)] [[PubMed](#)]
5. Tu, P.C.; Liang, Y.C.; Huang, G.J.; Huang, H.C.; Kao, M.C.; Lu, T.L.; Kuo, Y.H. New flavonoids, emarginin A-C from *Vaccinium emarginatum* Hayata. *Fitoterapia* **2020**, *141*, 104446. [[CrossRef](#)] [[PubMed](#)]
6. Kim, M.; Na, H.; Kasai, H.; Kawai, K.; Li, Y.S.; Yang, M. Comparison of Blueberry (*Vaccinium* spp.) and Vitamin C via Antioxidative and Epigenetic Effects in Human. *J. Cancer Prev.* **2017**, *22*, 174–181. [[CrossRef](#)]
7. Viskelis, P.; Rubinskiene, M.; Jasutiene, I.; Sarkinas, A.; Daubaras, R.; Cesoniene, L. Anthocyanins, antioxidative, and antimicrobial properties of American cranberry (*Vaccinium macrocarpon* Ait.) and their press cakes. *J. Food Sci.* **2009**, *74*, C157–C161. [[CrossRef](#)]
8. Kim, H.N.; Baek, J.K.; Park, S.B.; Kim, J.D.; Son, H.J.; Park, G.H.; Eo, H.J.; Park, J.H.; Jung, H.S.; Jeong, J.B. Anti-inflammatory effect of *Vaccinium oldhamii* stems through inhibition of NF-kappaB and MAPK/ATF2 signaling activation in LPS-stimulated RAW264.7 cells. *BMC Complement. Altern. Med.* **2019**, *19*, 291. [[CrossRef](#)]
9. Tu, P.C.; Liang, Y.C.; Huang, G.J.; Lin, M.K.; Kao, M.C.; Lu, T.L.; Sung, P.J.; Kuo, Y.H. Cytotoxic and Anti-inflammatory Terpenoids from the Whole Plant of *Vaccinium emarginatum*. *Planta Med.* **2020**, *86*, 1313–1322. [[CrossRef](#)] [[PubMed](#)]
10. Martineau, L.C.; Couture, A.; Spoor, D.; Benhaddou-Andaloussi, A.; Harris, C.; Meddah, B.; Leduc, C.; Burt, A.; Vuong, T.; Mai Le, P.; et al. Anti-diabetic properties of the Canadian lowbush blueberry *Vaccinium angustifolium* Ait. *Phytomedicine* **2006**, *13*, 612–623. [[CrossRef](#)]
11. Wang, L.; Zhang, Y.; Xu, M.; Wang, Y.; Cheng, S.; Liebrecht, A.; Qian, H.; Zhang, H.; Qi, X. Anti-diabetic activity of *Vaccinium bracteatum* Thunb. leaves' polysaccharide in STZ-induced diabetic mice. *Int. J. Biol. Macromol.* **2013**, *61*, 317–321. [[CrossRef](#)] [[PubMed](#)]
12. Del Bubba, M.; Di Serio, C.; Renai, L.; Scordo, C.V.A.; Checchini, L.; Ungar, A.; Tarantini, F.; Bartoletti, R. *Vaccinium myrtillus* L. extract and its native polyphenol-recombined mixture have anti-proliferative and pro-apoptotic effects on human prostate cancer cell lines. *Phytother. Res.* **2021**, *35*, 1089–1098. [[CrossRef](#)] [[PubMed](#)]

13. Landa, P.; Skalova, L.; Bousova, I.; Kutil, Z.; Langhansova, L.; Lou, J.D.; Vanek, T. In vitro anti-proliferative and anti-inflammatory activity of leaf and fruit extracts from *Vaccinium bracteatum* Thunb. *Pak. J. Pharm. Sci.* **2014**, *27*, 103–106. [[PubMed](#)]
14. Lee, J. Anthocyanin analyses of *Vaccinium* fruit dietary supplements. *Food Sci. Nutr.* **2016**, *4*, 742–752. [[CrossRef](#)]
15. Mannino, G.; Di Stefano, V.; Lauria, A.; Pitzonzo, R.; Gentile, C. *Vaccinium macrocarpon* (Cranberry)-Based Dietary Supplements: Variation in Mass Uniformity, Proanthocyanidin Dosage and Anthocyanin Profile Demonstrates Quality Control Standard Needed. *Nutrients* **2020**, *12*, 992. [[CrossRef](#)] [[PubMed](#)]
16. Li, H.L.; Lu, S.Y.; Yang, Y.P.; Tseng, Y.H. Ericaceae. In *Flora of Taiwan*, 2nd ed.; Huang, T.C., Ed.; Editorial Committee, Department of Botany, National Taiwan University: Taipei, Taiwan, 1998; pp. 17–39.
17. Sanchez-Rabeneda, F.; Jauregui, O.; Casals, I.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; Lamuela-Raventos, R.M. Liquid chromatographic/electrospray ionization tandem mass spectrometric study of the phenolic composition of cocoa (*Theobroma cacao*). *J. Mass Spectrom.* **2003**, *38*, 35–42. [[CrossRef](#)] [[PubMed](#)]
18. De Souza, L.M.; Cipriani, T.R.; Iacomini, M.; Gorin, P.A.; Sasaki, G.L. HPLC/ESI-MS and NMR analysis of flavonoids and tannins in bioactive extract from leaves of *Maytenus ilicifolia*. *J. Pharm. Biomed. Anal.* **2008**, *47*, 59–67. [[CrossRef](#)]
19. Lv, Q.; Luo, F.; Zhao, X.; Liu, Y.; Hu, G.; Sun, C.; Li, X.; Chen, K. Identification of proanthocyanidins from litchi (*Litchi chinensis* Sonn.) pulp by LC-ESI-Q-TOF-MS and their antioxidant activity. *PLoS ONE* **2015**, *10*, e0120480. [[CrossRef](#)] [[PubMed](#)]
20. Ben Said, R.; Hamed, A.I.; Mahalel, U.A.; Al-Ayed, A.S.; Kowalczyk, M.; Moldoch, J.; Oleszek, W.; Stochmal, A. Tentative Characterization of Polyphenolic Compounds in the Male Flowers of *Phoenix dactylifera* by Liquid Chromatography Coupled with Mass Spectrometry and DFT. *Int. J. Mol. Sci.* **2017**, *18*, 512. [[CrossRef](#)]
21. Rhourri-Frih, B.; Chaimbault, P.; Claude, B.; Lamy, C.; Andre, P.; Lafosse, M. Analysis of pentacyclic triterpenes by LC-MS. A comparative study between APCI and APPI. *J. Mass Spectrom.* **2009**, *44*, 71–80. [[CrossRef](#)]
22. Silveira, R.D.S.; Leal, G.C.; Molin, T.R.D.; Faccin, H.; Gobo, L.A.; Silveira, G.D.D.; Souza, M.T.D.S.; Lameira, O.A.; Carvalho, L.M.D.; Viana, C. Determination of phenolic and triterpenic compounds in *Jatropha gossypifolia* L by Ultra-high performance liquid chromatography-tandem mass spectrometric (UHPLC-MS/MS). *Braz. J. Pharm. Sci.* **2020**, *56*, 262. [[CrossRef](#)]
23. Allen, F.; Greiner, R.; Wishart, D. Competitive fragmentation modeling of ESI-MS/MS spectra for putative metabolite identification. *Metabolomics* **2015**, *11*, 98–110. [[CrossRef](#)]
24. Shoji, T.; Mutsuga, M.; Nakamura, T.; Kanda, T.; Akiyama, H.; Goda, Y. Isolation and structural elucidation of some procyanidins from apple by low-temperature nuclear magnetic resonance. *J. Agric. Food Chem.* **2003**, *51*, 3806–3813. [[CrossRef](#)] [[PubMed](#)]
25. Wang, C.M.; Li, T.C.; Jhan, Y.L.; Weng, J.H.; Chou, C.H. The impact of microbial biotransformation of catechin in enhancing the allelopathic effects of *Rhododendron formosanum*. *PLoS ONE* **2013**, *8*, e85162. [[CrossRef](#)]
26. Wang, C.M.; Hsu, Y.M.; Jhan, Y.L.; Tsai, S.J.; Lin, S.X.; Su, C.H.; Chou, C.H. Structure Elucidation of Procyanidins Isolated from *Rhododendron formosanum* and Their Anti-Oxidative and Anti-Bacterial Activities. *Molecules* **2015**, *20*, 12787–12803. [[CrossRef](#)] [[PubMed](#)]
27. Williams, A.R.; Ramsay, A.; Hansen, T.V.; Ropiak, H.M.; Mejer, H.; Nejsun, P.; Mueller-Harvey, I.; Thamsborg, S.M. Anthelmintic activity of trans-cinnamaldehyde and A- and B-type proanthocyanidins derived from cinnamon (*Cinnamomum verum*). *Sci. Rep.* **2015**, *5*, 14791. [[CrossRef](#)]
28. Wei, Y.; Xie, Q.; Ito, Y. Preparative Separation of Axifolin-3-Glucoside, Hyperoside and Amygdalin from Plant Extracts by High-Speed Countercurrent Chromatography. *J. Liq. Chromatogr. Relat. Technol.* **2009**, *32*, 1010–1022. [[CrossRef](#)] [[PubMed](#)]
29. Ahmad, R.; Ahmad, N.; Naqvi, A.A.; Exarchou, V.; Upadhyay, A.; Tuenter, E.; Foubert, K.; Apers, S.; Hermans, N.; Pieters, L. Antioxidant and Antiglycating Constituents from Leaves of *Ziziphus oxyphylla* and *Cedrela serrata*. *Antioxidants* **2016**, *5*, 9. [[CrossRef](#)]
30. Huang, S.P.; Ho, T.M.; Yang, C.W.; Chang, Y.J.; Chen, J.F.; Shaw, N.S.; Horng, J.C.; Hsu, S.L.; Liao, M.Y.; Wu, L.C.; et al. Chemopreventive Potential of Ethanolic Extracts of *Luobuma* Leaves (*Apocynum venetum* L.) in Androgen Insensitive Prostate Cancer. *Nutrients* **2017**, *9*, 948. [[CrossRef](#)]
31. Wang, C.M.; Yeh, K.L.; Tsai, S.J.; Jhan, Y.L.; Chou, C.H. Anti-Proliferative Activity of Triterpenoids and Sterols Isolated from *Alstonia scholaris* against Non-Small-Cell Lung Carcinoma Cells. *Molecules* **2017**, *22*, 119. [[CrossRef](#)]
32. Okoye, N.N.; Ajaghaku, D.L.; Okeke, H.N.; Ilodigwe, E.E.; Nworu, C.S.; Okoye, F.B. beta-Amyrin and alpha-amyrin acetate isolated from the stem bark of *Alstonia boonei* display profound anti-inflammatory activity. *Pharm. Biol.* **2014**, *52*, 1478–1486. [[CrossRef](#)] [[PubMed](#)]
33. Faccin, H.; Viana, C.; do Nascimento, P.C.; Bohrer, D.; de Carvalho, L.M. Study of ion suppression for phenolic compounds in medicinal plant extracts using liquid chromatography-electrospray tandem mass spectrometry. *J. Chromatogr. A* **2016**, *1427*, 111–124. [[CrossRef](#)] [[PubMed](#)]
34. Echard, J.P.; Benoit, C.; Peris-Vicente, J.; Malecki, V.; Gimeno-Adelantado, J.V.; Vaiedelich, S. Gas chromatography/mass spectrometry characterization of historical varnishes of ancient Italian lutes and violin. *Anal. Chim. Acta* **2007**, *584*, 172–180. [[CrossRef](#)] [[PubMed](#)]
35. Gu, J.Q.; Wang, Y.; Franzblau, S.G.; Montenegro, G.; Timmermann, B.N. Dereplication of pentacyclic triterpenoids in plants by GC-EI/MS. *Phytochem. Anal.* **2006**, *17*, 102–106. [[CrossRef](#)]
36. Saito, A.; Doi, Y.; Tanaka, A.; Matsuura, N.; Ubukata, M.; Nakajima, N. Systematic synthesis of four epicatechin series procyanidin trimers and their inhibitory activity on the Maillard reaction and antioxidant activity. *Bioorg. Med. Chem.* **2004**, *12*, 4783–4790. [[CrossRef](#)] [[PubMed](#)]

37. Maatta-Riihinen, K.R.; Kahkonen, M.P.; Torronen, A.R.; Heinonen, I.M. Catechins and procyanidins in berries of vaccinium species and their antioxidant activity. *J. Agric. Food Chem.* **2005**, *53*, 8485–8491. [[CrossRef](#)]
38. Jungfer, E.; Zimmermann, B.F.; Ruttkat, A.; Galensa, R. Comparing procyanidins in selected Vaccinium species by UHPLC-MS(2) with regard to authenticity and health effects. *J. Agric. Food Chem.* **2012**, *60*, 9688–9696. [[CrossRef](#)]
39. Zheng, W.; Wang, S.Y. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. *J. Agric. Food Chem.* **2003**, *51*, 502–509. [[CrossRef](#)]
40. De Bruyne, T.; Pieters, L.; Witvrouw, M.; De Clercq, E.; Vanden Berghe, D.; Vlietinck, A.J. Biological evaluation of proanthocyanidin dimers and related polyphenols. *J. Nat. Prod.* **1999**, *62*, 954–958. [[CrossRef](#)] [[PubMed](#)]
41. Ming, D.S.; Lopez, A.; Hillhouse, B.J.; French, C.J.; Hudson, J.B.; Towers, G.H. Bioactive constituents from Iryanthera megistophylla. *J. Nat. Prod.* **2002**, *65*, 1412–1416. [[CrossRef](#)]
42. Way, T.D.; Tsai, S.J.; Wang, C.M.; Jhan, Y.L.; Ho, C.T.; Chou, C.H. Cinnamtannin D1 from Rhododendron formosanum Induces Autophagy via the Inhibition of Akt/mTOR and Activation of ERK1/2 in Non-Small-Cell Lung Carcinoma Cells. *J. Agric. Food Chem.* **2015**, *63*, 10407–10417. [[CrossRef](#)] [[PubMed](#)]
43. Wang, H.; Song, L.; Feng, S.; Liu, Y.; Zuo, G.; Lai, F.; He, G.; Chen, M.; Huang, D. Characterization of proanthocyanidins in stems of Polygonum multiflorum Thunb as strong starch hydrolase inhibitors. *Molecules* **2013**, *18*, 2255–2265. [[CrossRef](#)] [[PubMed](#)]
44. CLSI. *Performance Standards for Antimicrobial Disk Susceptibility Tests*, 13th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018.
45. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*, 30th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020.